GLP-1 Drugs Like Ozempic May Help Reduce Migraine Symptom Severity
Recent research has found that GLP-1s may reduce the need for emergency care in those with chronic migraine. Image Credit: Maskot/Getty Images
A recent study suggests that GLP-1 drugs, like Ozempic, may make people with chronic migraine less likely to require emergency care.
People using GLP-1s may be less likely to need new preventive migraine medications.
AAAAI: GLP-1 Receptor Agonists Linked to Reduction in Asthma Exacerbation Risk
FRIDAY, March 6, 2026 — Glucagon-like peptide-1 (GLP-1) receptor agonist treatment is associated with reduced asthma exacerbation risk among individuals with overweight or obesity, without diabetes, according to a study presented at the annual…
AAOS: GLP-1 Receptor Agonist Use Increases Five-Year Risk for Osteoporosis
FRIDAY, March 6, 2026 — Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity is independently associated with a significantly increased five-year risk for osteoporosis, gout, and osteomalacia…
Some Patients Keep Weight off With Fewer GLP-1 Injections, Study Finds
FRIDAY, March 6, 2026 — Some patients taking popular GLP-1 weight loss drugs may be able to keep the weight off while taking injections less often, according to a small new study.The idea began when Dr. Mitch Biermann, an obesity and internal m…
Roche, Zealand’s Amylin Weight Loss Drug Fails To Clear Lilly’s Bar
Zealand Pharma’s shares fell 32% in early morning trading Friday after its Roche-partnered asset petrelintide failed to meet investor expectations in a mid-stage clinical trial.
How do GLP-1s affect bone health? New studies investigate
GLP-1 Weight-Loss Drugs Prove Effective Across Diverse Patient Groups
FRIDAY, March 6, 2026 — As the popularity of medications like Ozempic and Trulicity for losing weight continues to soar, folks may wonder: “Will they work for me?”Researchers at Johns Hopkins Bloomberg School of Public Health sought to shed light o…
Trial suggests GLP-1 combo therapy cuts fat while preserving muscle in obesity
A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also preserving lean mass, such as skeletal muscle and connective tissue. In the paper “Bimagrumab and semaglutide alone or in combination for the treatment of obesity: a phase 2 randomized clinical trial,” published Monday in the journal Nature Medicine, Dr. Steven Heymsfield of Pennington Biomedical Research Center describes the results of the BELIEVE study, which showed that the therapy combination addressed lean mass loss associated with GLP-1-based therapies.
STAT+: Omada reports first profitable quarter as it seizes broad GLP-1 opportunity
Virtual chronic care company Omada, which went public less than a year ago, reported a quarterly profit for the first time.
GLP-1 Drugs May Prevent, Treat Multiple Addictions
(MedPage Today) — Initiation of a GLP-1 receptor agonist was tied to lower risks of several substance use disorders (SUDs) in adults with type 2 diabetes, according to a target trial emulation using data on veterans.
In patients without a history…